TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Pelthos Therapeutics
Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to expand patient access to ZELSUVMI, its FDA-approved topical gel for treating molluscum contagiosum, which affects an estimated 16.7 million people annually.

Insights
WMT   positive

Highlighted as a top holding in the revenue-weighted ETF, indicating diversification


PTHS   positive

Company achieved a significant milestone by signing a PBM agreement that will expand patient access to their newly launched ZELSUVMI treatment, potentially increasing market reach and revenue